FDA & RUO

What changed on April 15, where each of the twelve actually sits right now, and the paperwork nobody selling you these is mentioning.

A lab tested 6,441 peptide vials. Here's how to read a COA so you know which side of the results you landed on.

UCLA counted 565 studies. Hundreds of thousands of users counted something else. Here's how to read both without getting played.

The letters list bacteriostatic water as evidence. Here is what that means for the stores you buy from.

What suppliers in China and Hong Kong are telling us, why US compounding pharmacies are low too, and how the vendors inside the network are getting ahead of it.

The 503A vote is about compounding eligibility, not approved treatments.

What actually changed in the peptide industry in 2026 — and what didn't.

The 3 things to check before you trust any vendor.

A GLP-1 pill with no food or water restrictions. Here’s what it means.

14 peptides are still Category 2. Here’s the real status.

Speed and certainty rarely coexist in biology.

Hype cycles don’t kill molecules. Ignorance does.

Risk doesn’t disappear just because people ignore it.

That changes the responsibility.

When enforcement rises, weak suppliers disappear.

The biggest shift in peptide access isn’t hype. It’s enforcement.

2026 is not business as usual. Here’s what’s happening.

The FDA just made that painfully clear.